Home > Quotes > CALA
CALA

Calithera Biosciences, Inc. Common Stock Quote & Summary Data

$3.65
*  
0.60
19.67%
Get CALA Alerts
*Delayed - data as of Dec. 21, 2016  -  Find a broker to begin trading CALA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CALA Pre-Market
 
 
Edit Symbol List
Symbol Lookup
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
CLOSEX

Edit Symbol List

Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.

Go Now
Clear List

Don't know the stock symbol? Use the Symbol Lookup tool.
Alphabetize the sort order of my symbols

CLOSEX
 

Symbol Lookup

 Save Stocks
Best Bid/Ask "Best Bid" is the highest price currently being offered for a block of stock.
"Best Ask" is the lowest price currently being asked for a block of stock. 		N/A / N/A
1 Year Target
Today's High /Low "Today's High" The highest sales price the stock has achieved during the regular trading hours, the intra-day high.
"Today's Low" The lowest sales price the stock has fallen to during the regular trading hours, the intra-day low. 		 / 
Share Volume "Share Volume" is the number of shares of the stock traded on the listing exchange during current trading hours. It does not include after hours volume.
50 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today's trading to the average daily volume. 296,146
Previous Close "Previous Close" is the previous trading day's last reported trade price during official trading hours. $ 3.05
52 Week High/Low "52 Week High" is the highest sales price the stock has achieved during the regular trading hours during the most recent 52 week period.
"52 Week Low" is the lowest sales price the stock has fallen to during the regular trading hours during the most recent 52 week period. 		$ 8.75 / $ 2.20
Market cap “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. “Market Capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements. $ 75,693,674
P/E Ratio "P/E Ratio" is a statistic calculated by dividing the price of a stock by the reported actual earnings per share of the issuing firm (not the same as the projected P/E ratio); it is also called the "multiple". NE
Forward P/E(1y) A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year. NE
Earnings Per Share (EPS) The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS. $ -1.95
Annualized dividend N/A
Ex Dividend Date The data is based on historical ex-dividend data & doesn’t include upcoming values. Visit the dividend history page to see the upcoming dividend information. N/A
Dividend Payment Date N/A
Current Yield Indicated yield represents annual dividends divided by current stock price. The data is based on historical ex-dividend data & doesn’t include upcoming values. Visit the dividend history page to see the upcoming dividend information. 0 %
Beta "Beta" is a volatility measurement of a stock mutual fund or ETF versus a comparable benchmark like the S&P 500 stock index. A stock fund or ETF with a higher beta than the S&P 500 will rise or fall to a greater degree. In contrast, a stock fund or ETF with a low beta will rise or fall less. 1.7
NASDAQ Official Open Price NASDAQ Official Opening Price: This process identifies the NASDAQ-specific opening prices for NASDAQ-listed issues. $ 3.80
Date of Open Price "Date of Open Price" This field refers to the date the NASDAQ Official Open Price was disseminated for a given stock. It is possible that the date will not be from the current trading day; this indicates that the stock didn't trade on NASDAQ during the current trading day. The NASDAQ Official Open Price is updated only when the stock is traded on NASDAQ. Dec. 21, 2016
NASDAQ Official Close Price "NASDAQ Official Closing Price (NOCP)" is a process for identifying the NASDAQ market-specific closing price for NASDAQ-listed issues. $ 3.65
Date of Close Price This field refers to the date the NOCP was disseminated for a given stock. It is possible that the date will not be from the prior day; this indicates that the stock didn't trade on NASDAQ on the prior day. The NOCP is updated only when the stock is traded on NASDAQ. Dec. 21, 2016
Community Sentiment

Intraday Chart

Company Description (as filed with the SEC)

We are a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule oncology drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Tumor metabolism and immuno-oncology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. We are developing agents that take advantage of the unique metabolic requirements of tumor cells and cancer-fighting immune cells such as cytotoxic T-cells. Our lead product candidate, CB-839, is an internally discovered, first-in-class oral inhibitor of glutaminase, a critical enzyme in tumor cells.  ... More ...  

Risk Grade

Where does CALA fit in the risk graph?


Risk Grade Scale

News for CALA


Consensus Recommendation


Additional Info



Smart Portfolio

Research Brokers before you trade

Want to trade FX?